# Celltrion: Phase 3 study closed enrollment, 473 enrolled (Refractory or Relapsed Multiple Myeloma)

**Score:** 100/100

| Field | Value |
|---|---|
| Sponsor | Celltrion |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma |
| NCT ID | NCT06952478 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | Refractory or Relapsed Multiple Myeloma |
| Intervention types | biological |
| Target enrollment | 473 |
| Site countries | Taiwan |
| Posted | 2025-05-01 |
| Planned start | 2025-08-12 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-27 |
| Last update posted | 2026-10-27 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.
- 473 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06952478). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.